Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2

COVID-19 is a global crisis of unimagined dimensions. Currently, Remedesivir is only fully licensed FDA therapeutic. A major target of the vaccine effort is the SARS-CoV-2 spike-hACE2 interaction, and assessment of efficacy relies on time consuming neutralization assay. Here, we developed a cell fus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Min, Su, Pei-Yi, Castro, Danielle A., Tripler, Therese N., Hu, Yingxia, Cook, Matthew, Ko, Albert I., Farhadian, Shelli F., Israelow, Benjamin, Dela Cruz, Charles S., Xiong, Yong, Sutton, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263067/
https://www.ncbi.nlm.nih.gov/pubmed/34166473
http://dx.doi.org/10.1371/journal.ppat.1009683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263067/
https://www.ncbi.nlm.nih.gov/pubmed/34166473
http://dx.doi.org/10.1371/journal.ppat.1009683

Ejemplares similares